Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial

Marianne Schell, Irada Pflüger, Gianluca Brugnara, Fabian Isensee, Ulf Neuberger, Martha Foltyn, Tobias Keßler, Felix Sahm, Antje Wick, Martha Nowosielski, Sabine Heiland, Michael Weller, Michael Platten, Klaus Maier‐Hein, Andreas von Deimling, Martin J. van den Bent, Thierry Gorlia, Wolfgang Wick, Martin Bendszus, Philipp KickingerederNeuro-Oncology 2020 · DOI

Abstract

ADClow is an independent prognostic parameter for stratifying OS and PFS in patients with recurrent glioblastoma. Consequently, the previously suggested role of ADClow as predictive imaging biomarker could not be confirmed within this phase II/III trial.
BibTeX
@inproceedings{schell2020validation,
  author = {Marianne Schell and Irada Pflüger and Gianluca Brugnara and Fabian Isensee and Ulf Neuberger and Martha Foltyn and Tobias Keßler and Felix Sahm and Antje Wick and Martha Nowosielski and Sabine Heiland and Michael Weller and Michael Platten and Klaus Maier‐Hein and Andreas von Deimling and Martin J. van den Bent and Thierry Gorlia and Wolfgang Wick and Martin Bendszus and Philipp Kickingereder},
  title = {{Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial}},
  booktitle = {Neuro-Oncology},
  year = {2020},
  doi = {10.1093/neuonc/noaa120},
}

Loading related content...

Figure